The development of a selective CDK7 inhibitor with anti-tumor activity

被引：0
|
作者：
Coombes, Raoul
Cheiper
Jogalekar, Ashutosh S.
Brackow, Jan
Ali, Simak
Heathcote, Dean
Kroll, Sebastian
Bodo, S.
Siwicka, Aleksandra
Periyasamy, Manikandan
Tolhurst, Robert
Kanneganti, Seshu
Snyder, James
Liotta, Dennis
Aboagye, Eric
Barrett, Anthony
机构：
[1] Univ London Imperial Coll Sci Technol & Med, London, England
[2] Emory Univ, Atlanta, GA 30322 USA
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3311
引用
收藏
页数：1
相关论文
共 50 条
  • [31] BAY 1112054, a highly selective, potent and orally available inhibitor of PTEFb/CDK9, shows convincing anti-tumor activity
    Scholz, Arne
    Luecking, Ulrich
    Siemeister, Gerhard
    Lienau, Philip
    Eis, Knut
    Wengner, Antje
    Petersen, Kirstin
    Boemer, Ulf
    Nussbaumer, Peter
    Choidas, Axel
    Ruehter, Gerd
    Eickhoff, Jan
    Schultz-Fademrecht, Carsten
    Klebl, Bert
    Ince, Stuart
    von Nussbaum, Franz
    Mumberg, Dominik
    Brands, Michael
    Ziegelbauer, Karl
    CANCER RESEARCH, 2014, 74 (19)
  • [32] TY-2699a is a highly potent CDK7 inhibitor to abolish dysfunctional tumor cell cycle for clinical development
    Dong, Shengli
    Liang, Apeng
    Zhu, Jian
    Wang, Huan
    Li, Meihua
    Wang, Kai
    Ni, Rongzhen
    Li, Haoyun
    Cao, Yundi
    Xiao, Linglin
    Li, Hongqiang
    Tu, Yian
    Zhou, Chao
    Gong, Aishen
    Xu, Shuyi
    Su, Hui
    Niu, Chengshan
    Jiang, Mingyu
    Xing, Feng
    Chen, Xiugui
    Chen, Shaoqing
    Li, Jun
    Wu, Yusheng
    CANCER RESEARCH, 2023, 83 (07)
  • [33] Anti-tumor activity of immunoproteasome selective inhibitors
    Parlati, Francesco
    Aujay, Monette
    Bedringaas, Siv Lise
    Demo, Susan
    Gjertsen, Bjorn
    Goldstein, Eileen
    Jiang, Jing
    Kirk, Christopher
    Laidig, Guy
    Lorens, James
    Lu, Yan
    Micklem, David
    Ruurs, Paulina
    Shenk, Kevin
    Sylvain, Catherine
    Sun, Congcong
    Woo, Tina
    Zhou, Han-Jie
    Bennett, Mark
    BLOOD, 2007, 110 (11) : 477A - 478A
  • [34] Activity of SY-5609, an oral, noncovalent, potent, and selective CDK7 inhibitor, in preclinical models of colorectal cancer.
    Johannessen, Liv
    Ke, Nan
    Sawant, Priyanka
    Dworakowski, Wojciech
    D'Ippolito, Anthony
    Hu, Shanhu
    Rajagopal, Nisha
    Eaton, Matthew
    Hodgson, Graeme
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
    Kwiatkowski, Nicholas
    Zhang, Tinghu
    Rahl, Peter B.
    Abraham, Brian J.
    Reddy, Jessica
    Ficarro, Scott B.
    Dastur, Anahita
    Amzallag, Arnaud
    Ramaswamy, Sridhar
    Tesar, Bethany
    Jenkins, Catherine E.
    Hannett, Nancy M.
    McMillin, Douglas
    Sanda, Takaomi
    Sim, Taebo
    Kim, Nam Doo
    Look, Thomas
    Mitsiades, Constantine S.
    Weng, Andrew P.
    Brown, Jennifer R.
    Benes, Cyril H.
    Marto, Jarrod A.
    Young, Richard A.
    Gray, Nathanael S.
    NATURE, 2014, 511 (7511) : 616 - +
  • [36] Effect of CDK7 inhibitor on MYCN-amplified retinoblastoma
    Xu, Hanyue
    Xiao, Lirong
    Chen, Yi
    Liu, Yilin
    Zhang, Yifan
    Gao, Yuzhu
    Man, Shulei
    Yan, Naihong
    Zhang, Ming
    BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS, 2023, 1866 (03):
  • [37] Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
    Nicholas Kwiatkowski
    Tinghu Zhang
    Peter B. Rahl
    Brian J. Abraham
    Jessica Reddy
    Scott B. Ficarro
    Anahita Dastur
    Arnaud Amzallag
    Sridhar Ramaswamy
    Bethany Tesar
    Catherine E. Jenkins
    Nancy M. Hannett
    Douglas McMillin
    Takaomi Sanda
    Taebo Sim
    Nam Doo Kim
    Thomas Look
    Constantine S. Mitsiades
    Andrew P. Weng
    Jennifer R. Brown
    Cyril H. Benes
    Jarrod A. Marto
    Richard A. Young
    Nathanael S. Gray
    Nature, 2014, 511 : 616 - 620
  • [38] In vitro and in vivo anti-tumor activity of ARQ 751, a potent and selective AKT inhibitor
    Yu, Yi
    Savage, Ronald E.
    Eathiraj, Sudharshan
    Hall, Terence
    Schwartz, Brian
    Abbadessa, Giovanni
    CANCER RESEARCH, 2016, 76
  • [39] Sustained proteasome inhibition by carfilzomib, a selective proteasome inhibitor, enhances anti-tumor activity
    Aujay, Monette
    Demo, Susan
    Jiang, Jing
    Kirk, Christopher
    Parlati, Francesco
    Suzuki, Erika
    Woo, Tina
    Bennett, Mark
    CANCER RESEARCH, 2009, 69
  • [40] Selective inhibition of CDK7 ameliorates experimental arthritis in mice
    Yong Xia
    Li-Ying Lin
    Mei-Ling Liu
    Zheng Wang
    Hong-Hai Hong
    Xu-Guang Guo
    Guo-Quan Gao
    Clinical and Experimental Medicine, 2015, 15 : 269 - 275
12345